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Abstract: Recent pharmaceutical research has focused on controlled drug delivery having 
an advantage over conventional methods. Adequate controlled plasma drug levels, reduced 
side effects as well as improved patient compliance are some of the benefits that these 
systems may offer. Controlled delivery systems that can provide zero-order drug delivery 
have the potential for maximizing efficacy while minimizing dose frequency and toxicity. 
Thus, zero-order drug release is ideal in a large area of drug delivery which has therefore 
led to the development of various technologies with such drug release patterns. Systems 
such as multilayered tablets and other geometrically altered devices have been created to 
perform this function. One of the principles of multilayered tablets involves creating a 
constant surface area for release. Polymeric materials play an important role in the 
functioning of these systems. Technologies developed to date include among others: 
Geomatrix
® multilayered tablets, which utilizes specific polymers that may act as barriers 
to control drug release; Procise
®, which has a core with an aperture that can be modified to 
achieve various types of drug release; core-in-cup tablets, where the core matrix is coated 
on one surface while the circumference forms a cup around it; donut-shaped devices, which 
possess a centrally-placed aperture hole and Dome Matrix
® as well as “release modules 
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assemblage”, which can offer alternating drug release patterns. This review discusses the 
novel altered geometric system technologies that have been developed to provide controlled 
drug release, also focusing on polymers that have been employed in such developments. 
Keywords: controlled drug delivery; geometrically altered devices; multilayered tablets; 
polymeric materials; “release modules assemblage” 
 
1. Introduction 
Modified or controlled release oral drug delivery systems have, over the last few decades, been 
shown to offer advantages over conventional systems [1–6]. These include increased patient 
compliance [7,8], selective pharmacological action; reduced side-effect profile and reduced dosing 
frequency [9]. These systems may therefore have a significantly beneficial outcome in therapeutic 
efficacy. Controlled release offers prolonged delivery of drugs and maintenance of plasma levels 
within a therapeutic range [10,11]. Furthermore, by pairing drug administration rate with drug 
elimination rate, steady-state plasma levels can be maintained [12,13]. Currently most drug delivery 
systems exhibit first-order drug release kinetics where the plasma level of the drug is extremely high 
after administration and then decreases exponentially. This poses disadvantages such as minimal 
therapeutic efficacy due to reduced drug levels; or drug toxicity which can occur at high 
concentrations [14]. This type of drug release does not allow for appropriate plasma drug level balance. 
Peak-to-trough fluctuations (as depicted in Figure 1) may occur with first-order drug release that may 
cause dose dependent side effects [15,16]. 
Figure 1. Plasma drug concentration versus time profile exhibiting the effect of zero-order 
drug release on plasma drug levels (adapted from Shahiwala et al. [15]). 
 
Drug delivery systems should ideally exhibit zero-order drug release kinetics which allows for a 
constant quantity of drug to be released over an extended period of time, resulting in uniform and 
sustained drug delivery [2,17–21]. Zero-order is a desired drug release kinetic in antibiotic delivery, 
the treatment of hypertension, pain management, antidepressant delivery and numerous other 
conditions that require constant plasma drug levels [14,22,23]. Thus, various studies have been Int. J. Mol. Sci. 2012, 13                 
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undertaken attempting to develop systems that are easily able to provide zero-order or near zero-order 
drug release [24–31]. 
The utilization of geometric principles have for many years been considered and employed in order 
to modify drug release behavior from non-linear to zero-order or near zero-order release kinetics [32–38]. 
Thus far researchers have attempted to control dissolution behavior of drug delivery systems by 
modifying and controlling the geometry of the employed devices e.g., geometries such as spherical, 
cylindrical, holed cylindrical and biconvex devices [39–41]. 
One of the principles involved in altering the geometry of tablets is to create a constant surface area 
for drug release to enable the achievement of zero-order kinetics [42,43]. Systems such as multilayered 
tablets, donut-shaped tablets, Procise
®, Geomatrix
® and Smartrix
® technologies have been developed 
employing geometric manipulations [5,36,40,44,45]. These geometric manipulations may also be 
employed to develop drug delivery systems for the treatment of specialized biological conditions 
where zero-order drug release is not optimal, for example chronotherapy for heart conditions [46] or 
the scheduled treatment of asthma and inflammation [47]. Bimodal drug release may also be desirable 
with drugs that have variable absorption sites along the gastro-intestinal tract [12,48]. Technologies 
such as the Dome Matrix
® have shown promise in achieving varied drug release profiles in order to 
treat specific conditions [47]. Dilacor XR™ was developed as an extended release formulation for the 
delivery of diltiazem hydrochloride as described by Colombo and co-workers where the geometry of 
the system played an important role in the drug release profiles [49]. In addition, the polymeric 
materials used to construct these technologies play an important role in the functioning of these 
specialized systems [40,41]. Thus far, various types of polymers have been investigated for their 
ability to control drug release [50]. Polymers are the essential drug carriers of multilayered matrix 
tablets and their properties are an important factor in the behavior of these devices. In the past, 
polymers that were mainly employed for such purposes were the hydropolymers [40], while currently 
polymers investigated range from swollen and non-swollen [40,51], porous and non-porous [52–54] to 
erodible or non-erodible polymers [5,55].  
In general, the mechanisms by which polymers perform their functions are by erosion [56], 
dissolution and swelling [57]. Some studies have shown that drug release from hydrophilic polymer 
matrices exhibit a typical time dependent profile in which the drug release is controlled ensuring 
swelling of the polymer [58–62]. This review thus discusses the application of altered geometric 
technology and its role in controlled oral drug delivery, focusing primarily on the types of polymers 
that have been employed in developing geometrically modified systems, the interplay of system 
geometry and polymeric selection ultimately contributing to the type of drug release patterns that 
are attained. 
2. Multilayered Tablets for Controlled Drug Delivery 
Mutilayered systems (bilayered, triple-layered, quadruple-layered, etc.) are becoming increasingly 
recognized as controlled-release drug delivery systems [63]. These systems have been shown to be 
advantageous over typical tablet systems as depicted in Table 1. Namdeo expressed that multilayered 
tablets have demonstrated promise, possessing various benefits, namely the ability to prevent 
interactions between drugs and excipients; and by providing an array of release profiles in one delivery Int. J. Mol. Sci. 2012, 13                 
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system of either the same or different drugs, treatment for conditions that require a regimen of more 
than one drug, immediate drug release using a disintegrating monolithic matrix in order to achieve an 
initial peak in plasma drug level, delayed drug release using an eroding monolithic matrix which may 
deliver another active drug to a different part of the gastrointestinal tract, providing controlled drug 
release instituting a swellable monolithic matrix and better control and regulation of release profiles by 
retarding initial burst release and achieving zero-order kinetics [64]. It would be beneficial if research 
focused on further modification of these systems for improved and comprehensive drug release 
capabilities that enable a larger scope of application in drug delivery.  
Table 1. Advantages of multi-layered tablets over conventional tablets (Adapted from 
Namdeo [64]). 
Conventional Tablet  Multi-Layered Matrix Tablets 
 
 
Drug is released in only one kinetic model 
May be used to incorporate more than one 
drug and separate them if any chemical 
incompatibilities exist. 
If more than one drug is incorporated, there is 
no way of avoiding chemical 
incompatibilities. 
Drug release behavior is not restricted to one 
type, this system may offer varied drug 
release kinetics of the same or different drugs 
such as extended and immediate release. 
Controlled-release multilayered tablets typically involve a drug core layer that is surrounded   
by barrier layers that may be made up of hydrophilic swellable polymers such as 
hydroxypropylmethylcellulose (HPMC) and poly(ethylene oxide) (PEO) or hydrophobic polymers 
such as ethylcellulose (EC) [4]. The barrier layers minimize and therefore delay the interaction of the 
gastrointestinal environment with the active core, by decreasing the surface area available for drug 
release or by controlling the rate at which the solvent penetrates the layers [40]. This allows the initial 
burst release to be minimized and therefore the drug release can be controlled at a near constant level 
while the barrier layers undergo erosion or swelling [5]. The swollen barrier layers undergo erosion as 
time goes on, thus increasing the surface area which ultimately allows more drug to be released. 
Following the same principle, it is possible to obtain a constant release profile as well as other types of 
dissolution patterns such as pulsatile or delayed delivery as well as extended drug delivery depending 
on the characteristics of the polymers employed. In either case the system should ideally erode 
completely (i.e., leaving no residue in the gastrointestinal tract after the entire amount of drug 
is released).  
The different types of multilayered tablet designs with varying drug release behaviors are shown in 
Figure 2 [65]. There are multilayered tablets that can provide zero-order sustained release where the 
tablet consists of either a hydrophilic or hydrophobic core layer with barrier layers that are press 
coated to the surfaces of the core layer. This leaves the sides of the core layer exposed. It has been 
shown that generally constant drug release can be achieved when both barrier layers are hydrophilic Int. J. Mol. Sci. 2012, 13                 
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and the core layer is hydrophobic [4,25]. However, other factors also need to be controlled in order to 
achieve zero-order drug release. 
Figure 2. Various polymeric formulations of multilayered tablets and possible drug release 
behavior (adapted from Chidambaram et al. [65]) 
 
2.1. Geomatrix
® Multilayer Tablet Technology  
The Geomatrix
® multilayer tablet technology was developed by Conte and co-workers for constant 
drug release [44]. The technology includes triple-layered and bilayered tablets. The triple-layered 
tablet which is exemplified in Figure 3 consists of an active core which is a hydrophilic matrix layer 
and two polymeric barrier layers on either side that are hydrophobic or semi permeable [66,67]. The 
bilayered tablet consists of the drug layer and one barrier layer [68]. The barrier layer modifies the 
swelling rate of the active core and reduces the surface area available for diffusion of drug [69–70]. 
Zero-order drug release can be achieved with the Geomatrix
® system [5]; however release is limited to 
one drug. Int. J. Mol. Sci. 2012, 13                 
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Figure 3. A typical Geomatrix
® multilayered tablet (Source: Shionogi Pharma, Inc. [67]). 
Barrier layers 
control the surface 
area diffusion of 
drug from the core
A core of hydroxypropylmethylcellulose (HPMC) matrix that 
contains the active drug  
2.2. Sodas
® Multilayer Tablet Technology 
Sodas
® multilayer tablet technology (Figure 4) is a multilayer drug delivery system which focuses 
on the production of controlled release beads [71]. The Sodas
® technology is characterized by its 
inherent flexibility that enables the production of customized dosage forms that respond directly to 
individual needs such as pain and blood pressure. The technology essentially leads a pursatile drug 
release where the drug is released in pulses that are separated by defined time intervals. Examples of 
this technology include Ritalin
® LA and Focalin
® XR. They are both used to treat Attention Deficit 
Hyperativity Disorder (ADHD). They provide a once-daily pulsed profile that offers the patient 
efficacy throughout the day negating the need for taking the dose during working hours unlike the 
twice-daily dosing of the conventional immediate release tablet [71]. Benefits offered by the SODAS
® 
technology include: controlled absorption with resultant reduction in peak to trough ratios, targeted 
release of the drug to specific areas within the gastrointestinal tract, absorption independent of the 
feeding state, suitability for use with one or more active drug candidate, facility to produce 
combination dosage forms, “sprinkle dosing” by administrating the capsule contents with soft food, 
once or twice daily dose resembling multiple daily dose profiles [71]. 
Figure 4. A schematic representation of Sodas
® multilayer tablet technology (adapted from 
Elan drug technologies [71]). 
Release control 
polymer-2
Release control 
polymer-1
Protective coating
Core granules 
or crystals
Drug layer
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The earlier described studies have provided practical technical ideas in the development of 
multilayered tablets depending on the clinical applications of these systems. The studies have also 
provided insight on what strategies need to be considered for further application. Table 2 provides the 
summary of the polymers influencing the behavior and release characteristics of multilayered tablets. 
It is observed that there are great variations of multilayered tablet technology proving flexibility 
which affords possibilities for positive research development. With the intuitive selection of polymers 
and the appropriate employment of geometric principles, multilayered tablets may emerge as the future 
benchmark for the treatment of chronic diseases. However the difficulties that may occur with the 
scale up of more intricate layered drug delivery systems may be considered to be unfavorable to the 
pharmaceutical industry. The necessity of specialized equipment may add to the difficulties in 
commercialization of these systems.  
Table 2. Summary of the type of polymers influencing the behavior and release 
characteristics of multilayered tablets. 
Type of Polymer 
Used as Drug Carrier 
Type of Polymer Used 
in Barrier Layers 
Type/Dimensions  
of Tablet 
Drug Release 
Achieved 
Hydrophilic Hydrophilic  Bilayered  tablet 
Extended drug 
release 
Hydrophilic Hydrophobic  Bilayered  tablet 
Drug release retarded 
to lesser extent 
Hydrophobic 
Hydrophilic 
(Methocel
® K4M) 
Triple-layered tablet 
Zero-order drug 
release kinetics 
Hydrophobic (CW) 
hydrophobic  
(carnauba wax) 
Triple-layered tablet 
Non-linear drug 
release 
Hydrophobic (CW) 
Hydrophilic 
(Methocel
® K15M) and 
Hydrophobic (CW) 
Triple-layered tablet 
Zero-order drug 
release kinetics. 
Hydrophilic 
(HPMCAS&HPMC) 
Hydrophobic (EC)  Triple-layered tablet 
Zero-order release 
kinetics. 
2.3. Factors Affecting the Rate of Drug Release from Multilayered Tablets 
2.3.1. Polymers Employed in Multilayered Tablets 
Generally, a multilayered system should initially swell, then gel and ultimately slowly erode [4,72]. 
A study done by Efentakis and co-workers investigated the effect of polymeric substances on drug 
release. Hydrophilic and swellable polymers such as HPMC (Methocel
® K100M), microcrystalline 
cellulose (MC) and PEO and the hydrophobic polymer cellulose acetate propionate (CAP) were 
employed in this study in which venlafaxine HCl was used as the model drug. The study focused on a 
core tablet that contained venlafaxine HCl and Methocel K100M as the drug carrier. Bilayered and 
triple-layered tablets were prepared using the core tablet. The bilayered tablet consisted of a core tablet 
where one surface was covered with either Cellulose Acetate Phthalate (CAP) or Methocel E50LV, 
while both surfaces of the core tablet were covered with both of the polymers to form the triple-layered 
tablets [40]. Hydrophilic polymers were employed as drug core matrices due to their swelling   Int. J. Mol. Sci. 2012, 13                 
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ability [73–76]. The release profiles obtained demonstrated that drug release was slower from the 
multilayered tablets than from the core tablet alone [40]. When the core tablet came into contact with 
the dissolution medium, it swelled and expanded. This caused an increase in the diffusion path length 
for the drug and the drug release rate was therefore reduced. Upon employing HPMC as a barrier layer, 
the layer swelled concurrently with the core tablet, merging the core surfaces thereby enveloping part 
of the core, which resulted in the limiting of drug transport through the barriers [40]. CAP did not 
swell due to its impermeability and therefore drug dissolution and the drug release rate was retarded. 
The use of HPMC or CAP in the barrier layers showed similar results in terms of retarding drug 
release except that Methocel showed slow erosion as opposed to CAP [40]. Generally, HPMC devices 
presented with slower drug release when compared to CAP devices ,the reason being that they form a 
more efficient and solid barrier. Overall, the study showed that the characteristics of the polymers 
employed had a significant influence on the release profiles of the tablets although the choice of 
polymers employed in the study was conservative. Further research that focuses on the use of novel 
specialized polymers that are competent in providing zero-order drug release is necessary. 
A study performed by Chidambaram and co-workers assessed the behavior of layered diffusional 
matrices for zero-order sustained drug release. Layered tablets were formulated with a hydrophobic 
core layer which contained the drug; this layer typically consisted of 24% 
w/w pseudoephedrine HCl, 
40% 
w/w carnauba wax and lactose filler. The barrier layers were composed of either hydrophilic 
(Methocel
® K4M or K100M or Avicel PH 101) or hydrophobic polymers. Three different types of 
matrices were formulated. In the first type, the two barrier layers were hydrophilic, in the second type, 
one of the barriers was hydrophobic while the other was hydrophilic and in the third type, the two 
barrier layers were both hydrophobic [65]. Results showed that more desirable linear release profiles 
were obtained with the first and second type of matrices as depicted in Figure 2a,d, while the barrier 
layers in the third system needed to be manipulated in order to achieve zero-order release   
kinetics [25,65]. The proposed mechanism for the zero-order drug release from the first type of matrix 
was that as the hydrophilic barriers swelled and eroded, the rate of diffusion of drug from the 
hydrophobic middle layer decreased [65,77]. According to the study, the release rate from the lateral 
surface was influenced by polymer viscosity and concentration. These factors ultimately influence 
diffusion path length as well as the diffusion co-efficient. The use of polymers that possess mechanical 
or chemical characteristics to intrinsically alter the geometry, via modification of the diffusion path 
length, of matrices for controlled release may be an interesting perspective to study for future drug 
delivery research. 
2.3.2. Structure of the Device 
A study undertaken by Efentakis and co-workers illustrated that the structure of a system plays an 
important role in its drug release behavior. They found that covering a larger area of the core tablet by 
a barrier layer results in the retardation of drug release to a greater extent, as it forms a more efficient 
barrier thereby decreasing the drug release rate [40]. Another study by Efentakis and Peponaki   
re-iterated the significance of structure and geometry of triple-layered tablets with isosorbide 
mononitrate as a model drug. The weight and thickness of the barrier layers also had a pivotal role in 
drug release behavior [70]. Chidambaram and co-workers established that drug release from the Int. J. Mol. Sci. 2012, 13                 
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surfaces of the core was dependent on the thickness of the hydrophilic barrier layers [65]. An 
investigation by Streubel and co-workers looked at bimodal drug release from multilayered matrix 
tablets. It was discovered that by increasing the weight of the barrier layers from 50 mg to 150 mg it 
resulted in a more effective retardation of drug release, thus it was concluded that by manipulating the 
weight and thickness of the outer layers (as shown in Table 2) a desirable drug release profile of 
individual drugs may be achieved, thus complementing their pharmacokinetic behavior [69]. The 
concept of barrier layers have proven to be beneficial in multilayered tablet designs; however 
converting the barrier layers into additional controlled release drug matrices may hold further potential 
for future application [64]. 
Zerbe and co-workers have shown that there are also complex multilayered tablet systems with 
layers of various shapes that are able to provide zero-order drug release. The Smartrix
® tablet 
technology (Figure 5) that was developed by LTS Lohmann Therapie-Systeme employs modified 
geometrical shapes that compensate for the varying surface area caused by erosion or swelling 
(displayed in Table 3) [78]. The triple layered tablet is composed of a drug core that has a specific 
shape. The core is enclosed between two rapidly erodible outer layers. The middle layer has a biconcave 
shape that the two outer layers tightly bond to after compression. The thickness of the outer layers and 
the shape of the drug core control the release of drug usually in a linear fashion. The Smartrix
® system 
is also able to achieve bimodal drug release [79], as an added advantage of being flexible. This 
technology has proven to be useful as it does not require specialized polymers to perform the desired 
function. The study that emanated in the development of the Smartrix
® system has further emphasized 
the functionality of shape and geometry in altering drug release behavior. However, this technology 
requires specialized dry tablet press machines that may pose as a disadvantage. 
Figure 5. Smartrix
® technology (Adapted from Zerbe and Krumme [78]). 
 
Table 3. Summary of various technologies that utilize geometric factors in drug delivery. 
Technology Design 
Factors Affecting Drug 
Release 
Type of Drug Release 
That May Be Achieved
Geomatrix
® Triple/bilayered  tablet. 
Type of polymer used, 
thickness of layers. 
Zero-order kinetics 
Smartrix
® 
Triple-layered tablet with core 
layer having a specific shape 
different to that of the outer 
layers. 
Shape of core layer. 
According to shape of 
core, zero-order kineticsInt. J. Mol. Sci. 2012, 13                 
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Table 3. Cont. 
Procise
® 
Uniformly dispersed drug core 
containing a hole. 
Geometry of core 
According to geometry 
of core, zero-order 
kinetics 
Dome Matrix
®/ 
“Release modules 
assemblage” 
Elementary module containing a 
concave base side and a convex 
base side. Various arrangements 
of modules to form different 
structures 
Arrangement of modules, 
type of polymeric  
material used. 
Various according to 
arrangement of modules 
e.g., Concave base 
attached to concave 
base. 
Core-in-cup 
devices 
Disc-shaped core compression 
coated on one surface and 
circumference to form a cup 
around it. 
Type of polymer, 
dimensions of core  
and cup. 
Zero-order kinetics 
Doughnut-shaped 
tablets 
Single/triple-layered  
tablets with a central hole/holes 
Size and number of holes, 
type of polymer used 
Zero-order kinetics 
Sodas
® Multilayer  tablet 
Type of polymer used, 
thickness of layers. Shape 
of core layer 
Pursatile drug release 
VersaTab
®  Bilayered tablet  Core drug, polymer layers 
Immediate release and 
controlled release 
Geolock
TM  Triple layered tablet 
Polymer layers, single or 
combination of drugs in 
the inner core 
Immediate or modified 
release 
2.4. Bilayered Tablets 
Bilayered tablets have proven to be effective in delivering drugs that require a loading dose 
followed by a maintenance dose [80–83]. Commonly, in bilayered systems, one layer contains a 
quantity of drug for conferring immediate release, while the second layer contains a quantity of drug 
for extended release. The rapid release layer disintegrates immediately after administration while the 
matrix layer remains intact during the passage of drug through the gastrointestinal tract. The matrix 
erodes in a controlled fashion in order to maintain blood levels. Two drugs may also be incorporated 
into this delivery system for variable release profiles. A bilayered tablet for the delivery of propranolol 
hydrochloride was developed by Patra and co-workers. These tablets were comprised of an immediate 
release layer and a sustained release layer. Sodium starch glycolate was employed as the 
superdisintegrant in the rapid release layers of various formulations, while the polymers Eudragit
® RL, 
Eudragit
® RS and EC were utilized in the sustained release layers. Drug release studies illustrated that 
there was an initial burst release that delivered the loading dose while the rest of the drug was released 
over 12 hours in a sustained manner [81]. The same concept has been demonstrated in a patent by Kim 
and co-workers where the system provided release of two drugs in different manners. The controlled 
release layer delivered metformin while the rapid release layer delivered glimepiride. The controlled 
release layer was made up of a mixture of hydrophobic and hydrophilic polymers, while the immediate 
release layer was composed of a disintegrant and glimepiride [82]. This further emphasizes the 
positive function of these systems in treating chronic conditions such as hypertension and diabetes. Int. J. Mol. Sci. 2012, 13                 
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Nirmal and co-workers developed a bilayered tablet containing atorvastatin calcium for immediate 
release and nicotinic acid for extended release for the concurrent treatment of hypercholesterolemia. It 
has been shown that the combination of these two drugs results in an important reduction of low 
density lipoprotein cholesterol as well as desirable variations in high density lipoprotein cholesterol [83]. 
Methocel
® K100M was employed as the polymeric matrix for nicotinic acid and the immediate release 
layer containing atorvastatin calcium was formulated using super disintegrant, croscarmellose sodium. 
Drug release studies were performed over 12 hours and the results indicated that these tablets were 
successful in delivering two types of drugs concurrently [83]. This bilayered system design may thus 
be valuable for future application in the successful treatment of hypertension. 
VersaTab
® Bilayered Tablet Technology  
A VersaTab
® bilayered tablet technology is a tablet that has been devised to result in a linear drug 
release through controlled erosion [84]. The technology designs tablets with the ability to co-release 
multiple drugs with different release rates. This technology is suitable for a large number of bioactives. 
The tablet is highly versatile with a broad range of delivery profiles and therefore endowed with 
improved patient compliance. Figure 6 displays profiles that depict VersaTab
®  bilayered tablet 
technology firstly with one bioactive that provide controlled release and secondly with two bioactives 
that provide immediate release and controlled release [84]. 
Figure 6. (a) VersaTab
® bilayered tablet; Profiles depicting VersaTab
® bilayered tablet 
technology: (b) One bioactive-controlled release; (c) Two bioactives-immediate release 
and controlled release. 
Time (h) Time (h)
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2.5. Triple-Layered Tablets 
Triple-layered tablets are comprised of an inner drug core layer which is sandwiched between two 
surrounding barrier layers [4,64]. These barrier layers may also contain drug and serve as matrices to 
release drug in various release patterns [64]. The general mechanisms of action of triple-layered tablets 
include erosion of matrix layers, creation of a drug concentration gradient, limiting surface area of 
release of the swellable matrix by the barrier layers, erosion and swelling of the barrier layers to 
achieve a constant area for uniform drug release, as well as varying of the layers dissolution to achieve 
pulsatile or alternating release profiles [40,64]. Triple-layered systems have some rewards in contrast 
to typical systems due to the varying release pattern capability, simplicity of manufacturing, reduced 
dosing frequency that leads to enhanced patient compliance, enhanced safety profile of drug levels and 
reduced cost. 
2.5.1. Geolock
TM Technology 
Geolock
TM Technology is a triple layered tablet that has been devised for chronotherapy   
focused-real time oral drug delivery [85]. Principally, it is a new clinically oral drug delivery 
technology which allows, with a high degree of precision, the timed delivery of drugs that employs a 
press-coating technique. Geolock
TM tablet is composed of an active drug core (middle layer) that is 
surrounded by two outer protective layers (Figure 7). The inner core can be a single or combination of 
drugs essentially formulated for either immediate or modified release. 
Figure 7. A schematic of a triple layered Geolock
TM tablet (Adapted from : SkypePharma [85]). 
Drug disk
Outer polymeric layers
 
2.5.2. Various Drug Release Profiles Achievable by Triple-Layered Tablets 
It has been shown that both immediate and sustained drug delivery can be obtained through a single 
triple-layered tablet [4]. In this case, there is an initial immediate rapid release of drug, which is 
followed by a sustained constant drug release. This type of release could be useful for drugs that need 
a high plasma concentration immediately for therapeutic efficacy where zero-order drug release kinetics 
is not required. Maggi and co-workers developed such a system where a quick/slow release of 
Naproxen was achieved [86]. A multi-layered controlled release tablet containing naproxen and naproxen 
sodium salt was developed by Desai in 1996. The tablet composition included a layer containing 
naproxen which offered a delayed release of a granulated form of naproxen and another immediate 
release layer that contained naproxen sodium salt. This system was designed to deliver a prompt Int. J. Mol. Sci. 2012, 13                 
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therapeutic effect while maintaining the effect for 24 hours [87]. This type of variable release is 
extremely useful for the delivery of specific drugs that need both rapid and sustained release.  
A patent by Iyer and his co-workers reported on a triple-layered system that was comprised of a 
sustained release layer containing methylcobalamin while the other two immediate release layers each 
contained an antihypertensive, and a lipid regulator or a serum homocysteine lowering agent providing 
a valuable combination for the treatment of hypertension [88]. Compressed mini-tablets were designed 
for biphasic delivery of drugs with zero-order release kinetics [88,89]. The mini-tablets were 
compressed within an outer filling that was composed of MC (Avicel PH102) that filled the space 
between the minitablets, this outer filling provided rapid drug release while the minitablets provided 
prolonged release [88]. The mini-tablets specifically were composed of either HPMC or EC, with a 
diameter of 2.5 mm and an approximate weight of 12 mg each. Various formulations that differed in 
the amount of outer filling and number of mini-tablets used were prepared. Results showed that the  
mini-tablets with HPMC showed the most potential for achieving zero-order drug release. Another 
patent by Zerbe and co-workers presented a multilayer triple-layered oral system that had a matrix core 
that contained an NSAID for sustained release and two surrounding layers each containing an   
H2-receptor antagonist. The first layer provided sustained release of the antagonist and the second 
layer provided a rapid release of the antagonist. This idea was developed for use in the treatment of 
osteoarthritis in people who are more susceptible to developing gastrointestinal adverse effects such as 
NSAID-induced ulcers [63]. 
Time-programmed or chronotherapeutic drug delivery can also be achieved with multi-layered 
tablets [4]. With chronotherapy, drug release is governed by time so that drug is released only when 
needed in accordance with the circadian rhythms of the body. This can be described as pulsatile release 
rather than continuous release. This type of delivery may be beneficial for preventing tolerance arising 
from the drug as well as in reducing the side-effects. Press coating is a good technique for producing 
this type of time-dependent release. With press coating, there are no specific coating solvents or 
equipment that is needed and therefore the manufacturing process is more efficient [90]. The core layer 
is essentially coated with polymeric barrier layers by compression. The drug is released when the 
barrier layers either swell or erode. The coating delays the interaction of the core with the fluid 
medium, which causes a lag time before the drug is released. When the solvent penetrates the core 
layer, the core swells and dissolves, this causes the coating shell to break thereby rapidly releasing the 
drug [4]. This research further confirms the useful flexibility of triple-layered tablets although the 
application is often limited to the release of one drug. 
It has been demonstrated that bimodal drug release may also be necessary when a non-uniform drug 
release rate is desired [69]. The mechanism of release typically involves an initial rapid release, 
followed by a slower constant release, which is then followed by another rapid release period. Bimodal 
drug release may be advantageous in that the initial rapid release phase which is followed by a slow 
release phase is able to compensate for the slow absorption of drug from the stomach and small 
intestine. More uniform delivery of drug into the systemic circulation can be achieved because 
bimodal release systems increase the rate of drug release when the ability of the body to absorb the 
drug decreases. Streubel and co-workers developed multilayered matrix tablets that could achieve 
bimodal drug release rates. Hydroxypropyl methylcellulose acetate succinate (HPMCAS) was used to 
form the matrix due to the fact that its solubility varies with pH. It is in essence, water soluble at high Int. J. Mol. Sci. 2012, 13                 
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pH values and water-insoluble at low pH values. The study aimed at determining the effect of 
HPMCAS on drug release from the different layers of the tablet [69]. 
The various geometries of triple-layered tablets may be quite useful for controlling the delivery of 
highly water soluble drugs. A study by Siahi and co-workers investigated the development of   
triple-layered tablets for the delivery of verapamil hydrochloride in a controlled manner. The tablets 
consisted of three layers that were prepared by compressing polymers which were either natural or 
semi-synthetic onto the sides of the drug core. HPMC, acacia and tragacanth were used as drug release 
delaying layers encompassing the core. Different formulations containing separate and combined 
amounts of these polymers were prepared. The results indicated that when tragacanth was used as a 
carrier, the release was delayed to a greater extent than when acacia was used. Results also showed 
that the location of the polymers in the triple-layered tablets had a substantial effect on the release 
kinetics [91].  
Triple-layer guar gum matrix tablet formulations were developed by Krishnaiah and co-workers in 
which the controlled delivery of water-soluble drugs using guar gum as a carrier was explored. The 
system was evaluated in terms of the release rate of trimetazidine dihydrochloride from the matrix. 
Different concentrations of guar (30% 
w/w, 40% 
w/w and 50% 
w/w) were used to prepare the triple-layered 
tablets. The guar gum acted as a release retardant. The release rate from these formulations enabled a 
twice daily administration of the delivery system [92].  
3. Multilayered Osmotic Devices 
An indented core tablet strategy for preparing monolithic osmotic pumps was developed by Longxiao 
and co-workers. The tablet was compressed by a punch using a needle. The indented core was coated 
using EC as a semipermeable membrane coating and polyethylene glycol (PEG) as a plasticizer 
together with sodium chloride as an osmotic agent, controlled membrane permeability. The tablet was 
developed for the delivery of atenolol and sodium chloride and was used as an osmotic agent. Results 
showed that the tablet was capable of delivering the drug constantly over 24 hours and was not 
dependent on the agitation or release medium [93]. This system does not require specialized laser drills 
to form the orifices, thus reducing manufacturing costs. The study was useful in attempting to develop 
a system that functioned as efficiently as an osmotic pump, however, in a more feasible and   
cost-effective manner. 
Longxiao and co-workers also prepared a bilayer osmotic pump tablet using the indented core 
strategy. The model drug used in the study was nifedipine. A modified tablet punch was used to 
prepare the tablets whereby the punch formed an indentation in the centre of the drug surface layer. 
The indentation was sprayed with a coating solution with only the bottom of the indentation being 
sufficiently coated. The sides of the indentation were not completely coated, which left an aperture 
where drug release could occur. The tablet demonstrated success in delivering nifedipine at a relatively 
constant rate for 24 hours [94]. 
A US patent by Faour and co-workers described a multilayered osmotic device that could deliver 
more than one pharmaceutical agent. The device was developed to deliver the first therapeutic agent 
by immediate release and the second in a controlled manner. The device consisted of a core that 
contained a therapeutic agent, an osmotic agent and poly (vinylpyrrolidone) (PVP). A similar device Int. J. Mol. Sci. 2012, 13                 
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patented by Fanner and co-workers consisted of a core was surrounded by a semipermeable membrane 
(Figure 8) that consisted of cellulose acetate esters and poly(ethylene glycol) (PEG) and contained a 
preformed passageway [95]. The semipermeable membrane was essentially permeable to the dissolution 
environment and impermeable to the therapeutic agent in the core. The device was also coated with a 
poly(vinylpyrrolidone)-(vinyl acetate) copolymer that partially or completely surrounded the 
semipermeable membrane and covered the passageway in the same manner as a plug. The final 
segment consisted of an external coat that was comprised of PVP and PEG and a second therapeutic 
agent that would be immediately released. When the external coat released the second agent, it eroded 
or dissolved thereby releasing the therapeutic agent contained in the core in a controlled manner. 
Figure 8. Schematic depiction of a multilayered osmotic device (Adapted from Fanner   
et al. [96]). 
 
4. Multilayered Floatable Drug Delivery Systems 
A study that was conducted by Fassihi and co-workers investigated zero-order release kinetics from 
a self-correcting floatable asymmetric configuration drug delivery system. Theophylline was the model 
drug while PEO polymers of various molecular weights were employed as drug carriers. The various 
types of PEO polymers, drug and excipients were directly compressed into a triple-layer asymmetric 
floatable device. The core layer contained theophylline while the outer layers were composed of 
polymers and excipients in order to delay the interaction of the core layer with water, thereby delaying 
and controlling the drug release. Dissolution studies over 16 hours showed that the entire amount of 
drug was released in a zero-order manner with no initial burst release [9]. The release was dependent 
on the thickness of the layers and polymers used.  
Fassihi and co-workers also investigated zero-order delivery of alfuzolin hydrochloride via a 
gastroretentive system. Triple-layered and bilayered matrices were developed by compressing PEO, 
HPMC, sodium bicarbonate, citric acid and PVP. Dissolution studies demonstrated the ability of the 
matrices to achieve floatation in pH 2 and pH 6.8 as well as providing zero-order drug release [97]. 
This system showed fine potential for providing enhanced bioavailability and targeted delivery to the 
small intestine. 
A study by Yang and co-workers proposed a drug delivery system that would be able to treat 
Helicobacter pylori-associated gastric ulcers. The system was comprised of a swellable, asymmetric 
triple-layered tablet that was also floatable so as to increase the gastric retention time of the system. 
The employed rate-controlling polymers were HPMC and PEO. The core layer of the triple-layered Int. J. Mol. Sci. 2012, 13                 
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tablet contained the drugs tetracycline and metronidazole. In vitro studies exhibited a sustained 
delivery of the two drugs over 6–8 hours, while the tablet was retained, showing the potential to 
achieve localized treatment, thereby improving therapeutic efficacy. This study poses great potential 
for the essential eradication of Helicobacter pylori infection that often results in hospitalization of 
patients who develop serious ulcers [98]. 
A patent awarded to Doshi and co-workers described a floatable drug delivery system that is able to 
deliver multiple drugs. The system was bilayered and was able to deliver a drug from one layer 
immediately, followed by slow and controlled release of another drug from the other matrix-forming 
layer. The immediate release layer contained a disintegrating agent while the matrix-forming layer 
consisted of a gas generating component and a gelling agent [80]. The aim of this system was to attain 
a controlled delivery of fluoroquinolones and to maintain the plasma levels of the drugs within a 
therapeutic range with once daily administration. 
5. Core-in-Cup Devices  
Danckwerts developed a core-in-cup tablet system that was able to provide zero-order drug release 
of aqueous-soluble and aqueous-insoluble drugs. The system consisted of a disc-shaped matrix core 
that was compression-coated on one surface as well as at the circumference in order to form a cup 
around the core. Drug was released in a sustained manner from one stable surface that had a constant 
surface area. By manipulating the grade, quantity and exposed surface area of any hydrophilic polymer 
or mixture of polymers that erode constantly over time, the core-in-cup compressed tablet is able to 
deliver a constant amount of drug over time [99]. Results showed that the system was able to provide 
zero-order drug release for time intervals between 8 and 23 hours, the time of linear release was 
approximately 8 hours when 5% 
w/w HPMC K4M with caffeine core-in-cup tablets were produced and 
approximately 23 hours when 15% 
w/w HPMC K15M in ibuprofen core-in-cup tablets were produced. 
The research that has been conducted on core-in-cup devices showed several interesting and useful 
techniques as well as beneficial application in terms of the solubility of drugs, the flexibility of 
delivering both aqueous soluble and aqueous insoluble drugs pose an advantage. 
Danckwerts also studied the effectiveness of cup tablets of different depths for use in core-in-cup 
tablets and the optimal formulation in terms of drug release behavior. He developed a specific punch 
that is able to change the depth of the cup tablet, thus allowing it to carry various cores in terms of 
hardness and mass. The efficiency of cup tablets with varying depths and the optimal formulation in 
terms of drug release were investigated in the study. The cup tablets were composed of 15% 
w/w 
carnauba wax in EC while the core tablets were composed of 5% 
w/w HPMC K4M in ibuprofen. The 
results indicated that Ibuprofen was released at a near zero-order rate for 18 hours for the cup tablets 
that had a final depth of 4 mm [99]. Figure 9 shows the typical geometries of core-in-cup tablets. Int. J. Mol. Sci. 2012, 13                 
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Figure 9. Typical geometries of core-in-cup tablets (Source: Guimarães et al [100]). 
 
6. Procise
® Technology 
The Procise
® device has a specific geometric configuration (as depicted in Figure 5) that controls 
drug release behavior [36]. It is composed of a core which contains uniformly dispersed drug with a 
core hole in the middle (Figure 10). It has been made known that, altering the geometry of the core can 
change the drug release kinetics into zero-order or even first order if desired (as indicated in Table 2). 
The core’s entire surface besides the surface of the cylindrical face is surrounded by a permeable 
inactive coat so that drug release occurs solely from the cylindrical area. The device is also able to 
deliver up to two drugs simultaneously with varying release profiles [36]. This technology further adds 
to the varied geometrical systems for flexible and simplified drug delivery. 
Figure 10. (a) Aerial schematic of Procise
® technology; (b) Two-dimensional schematic of 
Procise
® technology (adapted from Porter [79]). 
 
7. Donut-Shaped Devices for Controlled Drug Delivery 
There are various publications dating rather far back that established that zero-order release kinetics 
could be achieved from a hemispherical device containing a hole [42,45,101–105]. A study by Kim 
investigated drug release from uncoated compressed tablets that contained a single central hole. The 
impact of the hole size and drug solubility on drug release was also investigated. The tablets were 
composed of PEO and had a diameter of 12 mm. Theophylline was used as the model drug. The tablets 
provided zero-order drug release for approximately 80–90% of the drug followed by a decreased drug 
release rate. The results also indicated that as the size of the hole increased, the rate of drug release 
also increased. Drug solubility proved to be inversely proportional to duration of linear drug   
release [104]. It was concluded that the donut-shaped PEO tablets with an aperture were capable of 
providing zero-order drug release as the effect of surface area on release kinetics is reduced. The 
geometric factors that influence the drug delivery of donut-shaped tablets are shown in Table 2.  Int. J. Mol. Sci. 2012, 13                 
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The hydrophilic polymer based donut-shaped tablets developed by Kim, exhibited a disadvantage 
as they adhered to biological tissues and solids causing dose dumping of the drug [45]. It was due to 
this reason that Kim, decided to undertake a study on coated donut-shaped tablets for parabolic and 
linear drug release. Two types of polymers, namely rapidly erodible and slowly erodible polymers, 
were investigated. Zero-order release was achieved when the slowly erodible polymers were used and 
parabolic drug release was achieved when rapidly erodible polymers were used when diltiazem 
hydrochloride was incorporated as a model drug. It was also found that the drug release characteristics 
depended on the stirring rate and hole size [45]. These tablets did not adhere to either biological tissues 
or solids, thus proving to be more effective than the uncoated systems [45]. HPMC donut-shaped 
tablets were developed and investigated by Cheng and co-workers. Theophylline and diltiazem 
hydrochloride were employed as model drugs. Results depicted that zero-order kinetics was achieved 
for approximately 90% of the duration of the study. An increase in the size of the centre hole caused an 
increase in the rate of drug release and a longer duration of zero-order release [105]. A further study 
was conducted by Kim on triple-layered donut-shaped tablets (Figure 11) with enteric polymers to 
evaluate their controlled release ability. The tablets were prepared by layering three powders and 
compressing them with a punch. HPMCAS was the fundamental polymer of the core while the outer 
layers were composed of EC. The results showed that the solubility of the drugs had an effect on 
release kinetics. The hydrochloride salts of weakly basic drugs had a slower release rate than neutral 
drugs [66]. Thus, this system is capable of providing zero-order drug release for drugs with   
varying solubilities. 
Figure 11. A schematic of a triple-layered, donut-shaped tablet (adapted from Kim   
et al. [66]). 
 
A study completed by Sundy and co-workers developed a novel compression-coated doughnut-shaped 
tablet for zero-order sustained release. The tablets were also assessed for their reproducibility. The 
tablets were prepared using a unique designed punch set. Hydrophilic and hydrophobic polymers were 
employed and evaluated as the coating layers. Caffeine and ibuprofen were used as model drugs as 
they have different solubilities and allowed for a comparison on the drug release profiles. Results 
showed that a coating layer of HPMC K15M and a core layer of HPMC K4M provided zero-order Int. J. Mol. Sci. 2012, 13                 
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release of both caffeine and ibuprofen [42]. The tablets also proved to be feasible to manufacture on a 
larger scale. 
8. Dome Matrix
® and “Release Modules Assemblage” Technology 
The dome matrix technology (described in Table 3) was developed by Losi and co-workers. The 
elementary module (depicted in Figure 12a) is a swellable matrix device comprising of a concave base on 
one end and a convex base on the other end. Losi and co-workers also developed the “release modules 
assemblage” technology which implies the creation of different drug delivery systems, having various 
functions by the assemblage of two or more of the elementary/release modules. Figure 6 illustrates the 
dome matrix modules and examples of the possible assemblages that may be achieved. The drug 
release patterns from these assemblages depended on the manner in which the modules were placed or 
attached to each other [47]. For example, multi-kinetics can be achieved and the delivery of two drugs 
in a single unit at a specific time and at a specific rate can is also possible. Two types of assemblages 
were mentioned in this study, the first was called “piled configuration” (depicted in Figure 12c) where 
the convex base of one module is inserted into the concave base of another module and the second was 
called “void configuration” (depicted in Figure 12b) where the concave base of one module is fixed 
onto the concave base of another module creating a space/void between the two modules [47].  
Figure 12. (a) Dome matrix
® module; (b) “void” configuration; (c) “piled” configuration 
(Adapted from Losi et al. [47]). 
 
The modules were compared to flat base matrices in terms of drug release behavior. Buflomedyl 
pyridoxal phosphate (BPP) was the model drug used in the study. The results depicted that the 
modules did not completely alter the kinetics compared to flat base matrices having the same weight 
and composition. However, the dome matrix
® had a higher initial release rate. The concave and convex 
bases themselves exhibited different release patterns, with the convex base releasing drug faster [47]. 
The technology proved to have potential benefits in terms of providing flexible drug release by 
increasing the amount of modules in an arrangement. This technology has various advantages although Int. J. Mol. Sci. 2012, 13                 
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the complexity of the systems may be a shortcoming of the system in terms of administration of the 
devices to patients. A summary of various technologies that utilize geometric factors in drug delivery 
is provided in Table 3. 
9. Conclusions  
It has been elucidated that geometrically altered drug delivery systems, especially multilayered 
tablets, have provided various advantages to drug delivery technology. The ease of manufacture of 
these systems adds further benefit in terms of cost. These systems therefore show promise for 
therapeutic use in the future. The technology that these systems encapsulate, offers valuable knowledge 
and insight for the inspiration of more intricate and constructive drug delivery systems for wider 
applications. Future research may thus focus further on modifying these systems and using the basic 
technological principles to develop novel systems that may be able to be applied in broader and more 
complicated drug delivery, such as in the treatment of more complex diseases with a larger drug 
regimen that requires more individualized types of drug release. With the appropriate selection of 
polymer matrices and specialized geometries, these systems could be used to deliver more drugs in a 
more controlled manner for adequate time periods. The fact that drug delivery systems with altered 
geometric configurations (particularly tablets) have shown promising results in drug delivery technology 
and ease of manufacturing is an added advantage to the pharmaceutical industry. 
References 
1.  Deshpande, A.A.; Rhodes, C.T.; Shah, N.S.; Malick, A.W. Controlled-release drug delivery 
systems for prolonged gastric residence: An overview. Drug Dev. Ind. Pharm.  1996,  22,  
531–539.  
2.  Green, P.G. Iontophoretic delivery of peptide drugs. J. Control. Release 1996, 41, 33–48. 
3.  Rubinstein, A.; Friedman, M.; Baluom, M.; Tirosh, B. Controlled Release Oral Drug Delivery 
System. U.S. Patent 7,189,414, 13 March 2007. 
4.  Abdul, S.; Poddar, S.S. A flexible technology for modified release of drugs: Multi layered tablets. J. 
Control. Release 2004, 97, 393–405. 
5.  Yu, D.; Branford-White, C.; Ma, Z.; Zhu, L.M.; Li, X.Y.; Yang, X.L. Novel drug delivery 
devices for providing linear release profiles fabricated by 3DP. Int. J. Pharm.  2009,  370,  
160–166.  
6.  Varum, F.J.O.; Merchant, H.A.; Basit, A.W. Oral modified-release formulations in motion: The 
relationship between gastrointestinal transit and drug absorption. Int. J. Pharm. 2010, 395, 1–2, 
26–36. 
7.  Chien, T.W. Fundamentals of Controlled-Release Drug Administration. In Novel Drug Delivery 
System; Swarbrick, J., Ed.; Marcel Dekker Inc.: New York, NY, USA, 1982; pp. 465–574. 
8.  Wilding, I.R.; Coupe, A.J.; Davis, S.S. The role of gamma scintigraphy in oral drug delivery. 
Adv. Drug Deliv. Rev. 1991, 7, 87–117.  
9.  Fassihi, R.; Yang, L. Controlled Release Drug Delivery System. U.S. Patent 5,783,212,  
21 July 1998. Int. J. Mol. Sci. 2012, 13                 
 
 
38
10.  Singh, B.N.; Kim, K.H. Floating drug delivery systems: An approach to oral controlled drug 
delivery via gastric retention. J. Control. Release 2000, 63, 235–259. 
11.  Lingam, M.; Ashok, T.; Venkateswarlu, V.; Rao, Y.M. Design and evaluation of a novel matrix 
type multiple units as biphasic gastroretentive drug delivery systems. AAPS PharmSci. 2006, 9, 
1253–1261. 
12.  Shah, A.C. Design of Oral Sustained Release Drug Delivery Systems: In Vitro/in Vivo 
Considerations. In Oral Sustained Release Formulation Design and Evaluation; Yacobi, A., 
Halperin-Walega, E., Eds.; Pergamon: New York, NY, USA, 1988; pp. 35–56. 
13.  Hardy, I.J.; Windberg-Baarup, A.; Neri, C.; Byway, P.V.; Booth, S.W.; Fitzpatrick, S. 
Modulation of drug release kinetics from hydroxypropyl methyl cellulose matrix tablets using 
polyvinyl pyrrolidone. Int. J. Pharm. 2007, 337, 246–253. 
14.  Landgraf, W.; Li, N.H.; Benson, J.R. New polymer enables near zero order release of drugs. 
Drug Deliv. Technol. 2005, 5, 48–55. 
15.  Shahiwala, A.; Misra, A. Pulmonary absorption of liposomal levonorgestrel. AAPS PharmSci. 
2004, 5, doi:10.1208/pt050113. 
16.  Reed, R.C.; Dutta, S.; Liu, W. Once-daily dosing is appropriate for extended-release divalproex 
over a wide dose range, but not for enteric-coated, delayed-release divalproex: Evidence via 
computer simulations and implications for epilepsy therapy. Epilepsy Res. 2009, 87, 260–267.  
17.  Kim, C.J. Coated Tablet With Long Term Parabolic and Zero-Order Release Kinetics. U.S. 
Patent 6,110,500, 29 August 2000. 
18.  Sershen, S.; West, J. Implantable, polymeric systems for modulated drug delivery. Adv. Drug 
Deliv. Rev. 2002, 54, 1225–1235.  
19.  Vandamme, T.F.; Ellis, K.J. Issues and challenges in developing ruminal drug delivery systems. 
Adv. Drug Deliv. Rev. 2004, 56, 1415–1436.  
20.  Ayres, J.W. Coated, Platform-Generating Tablet. U.S. Patent 6,733,784, 11 May 2004. 
21.  Shivaraj, A.; Selvam, R.P.; Mani, T.T.; Sivakumar, T. Design and evaluation of transdermal drug 
delivery of ketotifen fumarate. Int. J. Pharm. Biomed. Res. 2010, 1, 42–47. 
22.  Siegel, S.; Winey, K. Long-Term Delivery Formulations and Methods of Use Thereof. U.S. Pat. 
Appl. 20080305140, 12 November 2008.  
23.  Cheng, P.; Chen, M.; Udipi, K. Dry Diazeniumdiolation Methods for Producing Nitric Oxide 
Releasing Medical Devices. U.S. Pat. Appl. 20100159119, 24 June 2010. 
24.  Varelas, C.G.; Dixon, D.G.; Steiner, C.A. Zero-order release from biphasic polymer hydrogels.  
J. Control. Release 1995, 34, 185–192.  
25.  Qiu, Y.; Chidambaram, N.; Flood, K. Design and evaluation of layered diffusional matrices for 
zero-order sustained-release. J. Control. Release 1998, 51, 123–130. 
26.  Pillay, V.; Fassihi, R. Electrolyte-induced compositional heterogeneity: A novel approach for 
rate-controlled oral drug delivery. J. Pharm. Sci. 1999, 88, 1140–1148. 
27.  Yang, L.; Fassihi, R. Zero-order release kinetics from a self-correcting floatable asymmetric 
configuration drug delivery system. J. Pharm. Sci. 2000, 85, 170–173. 
28.  Gallardo, A.; Rodríguez, G.; Aguilar, M.R.; Fernández, M.; San Román, J. A kinetic model to 
explain the zero-order release of drugs from ionic polymeric drug conjugates: Application to 
AMPS-Triflusal-Derived polymeric drugs. Macromolecules 2003, 36, 8876–8880.  Int. J. Mol. Sci. 2012, 13                 
 
 
39
29.  Andjelić, S.; Yuan, J.; Jamiolkowski, D.D.; Diluccio, R.; Bezwada, R.; Zhang, H.; Mijovic, J. 
Hydrophilic absorbable copolyester exhibiting zero-order drug release. Pharm. Res. 2006, 23, 
821–834.  
30.  Pryce Lewis, W.E.; Rowe, C.W.; Cima, M.J.; Materna, P.A. System for Manufacturing 
Controlled Release Dosage Forms, Such as Zero-Order Release Profile Dosage Form 
Manufactured by Three-Dimensional Printing. U.S. Patent 7,820,201, 26 October 2010.  
31.  Wang, S.X.; Bao, A.; Phillips, W.T.; Goins, B.; Herrera, S.J.; Santoyo, C.; Miller, F.R.;   
Otto, R.A. Intraoperative therapy with liposomal drug delivery: Retention and distribution in 
human head and neck squamous cell carcinoma xenograft model. Int. J. Pharm.  2009,  373,  
156–164.  
32.  Brooke, D.; Walshkuhn, R.J. Zero-order drug delivery system: Theory and preliminary testing.  
J. Pharm. Sci. 1977, 66, 159–162. 
33.  Ford, J.L.; Rubenstein, M.H.; McCaul, F.; Hogan, J.E.; Edgar, P.J. Importance of drug type, 
tablet shape and added diluents on drug release kinetics from hydroxypropylmethylcellulose 
matrix tablets. Int. J. Pharm. 1987, 40, 233–234. 
34.  Sangalli, M.E.; Conte, U.; Gazzaniga, A.; La Manna, A. Inert Monolithic Device with Central 
Hole for Constant Release. In Proceedings of the International Symposium of Controlled Release 
Bioactive Materials, Washington, DC, USA, 25–30 July 1993; Academic Press Inc.: New York, 
NY, USA, 1980; Volume 20, pp. 316–317. 
35.  Siepmann, J.; Streubel, A.; Peppas, N.A. Understanding and predicting drug delivery from 
hydrophilic matrix tablets using the “Sequential Layer”. Model. Pharm. Res. 2002, 19, 306–314. 
36.  Chopra, S.K. Drug Delivery Systems Based on Geometric Configuration. In Modified-Release 
Drug Delivery Technology; Rathbone, M.J., Hadgraft, J., Roberts, M.S., Eds.; Marcel Dekker: 
New York, NY, USA, 2002; pp. 35–48, doi:10.1201/9780203910337.ch4. 
37.  Cobby, J.; Mayersohn, M.; Walker, G.C. Influence of shape factors on kinetics of drug release 
from matrix tablets I: Theoretical. J. Pharm. Sci. 1974, 63, 725–732. 
38.  Sakamoto, J.H.; van de Ven, A.L.; Godin, B.; Blanco, E.; Serda, R.E.; Grattoni, A.; Ziemys, A.; 
Bouamrani, A.; Hu, T.; Ranganathan, S.I.; et al. Enabling individualized therapy through 
nanotechnology. Pharmacol. Res. 2010, 62, 57–89.  
39.  Cao, X.; Lai, S.; Lee, L.J. Design of a self-regulated drug delivery device. Biomed. Microdevices 
2001, 3, 109–118.  
40.  Efentakis, M.; Politis, S. Comparative evaluation of various structures in polymer controlled 
drug delivery systems and the effect of their morphology and characteristics on drug release. Eur. 
Polym. J. 2006, 42, 1183–1195.  
41.  Martin del Valle, E.M.; Galan, M.A.; Carbonell, R.G. Drug delivery technologies: The way 
forward in the new decade. Ind. Eng. Chem. Res. 2009, 48, 2475–2486.  
42.  Sundy, E.; Danckwerts, M.P. A novel compression-coated doughnut-shaped tablet design for 
zero-order sustained release. Eur. J. Pharm. Sci. 2004, 22, 477–485. 
43.  Dash, S.; Murthy, P.N.; Nath, L.; Chowdhury, P. Kinetic modeling on drug release from 
controlled drug delivery systems. Acta Pol. Pharm. 2010, 67, 217–223. 
44.  Conte, U.; Maggi, L.; Colombo, P.; Manna, L. Multilayered hydrophilic matrices as constant 
release devices. J. Control. Release 1993, 26, 39–47. Int. J. Mol. Sci. 2012, 13                 
 
 
40
45.  Kim, C.J. Release kinetics of coated, donut-shaped tablets for water soluble drugs. Eur. J. Pharm. 
Sci. 1999, 12, 237–242. 
46.  Survase, S.; Kumar, N. Pulsatile drug delivery: Current scenario. Curr. Res. Info. Pharm. Sci. 
2007, 8, 27–33. 
47.  Losi, E.; Bettini, R.; Santi, P.; Sonvico, F.; Colombo, G.; Lofthus, K.; Colombo, P.; Peppas, N.A. 
Assemblage of novel release modules for the development of adaptable drug delivery systems.  
J. Control. Release 2006, 111, 212–218. 
48.  Gohel, M.C.; Nagori, S.A. A novel colonic drug delivery system of ibuprofen. Asian J. Pharm. 
2009, 3, 233–239. 
49.  Colombo, P.; La Manna, A.; Conte, U. System for the Controlled-Rate Release of Active 
Substances. U.S. Patent 4,839,177, 13 June 1989.  
50.  Song, F.; Zhang, L.; Yang, C.; Yan, L. Genipin-crosslinked casein hydrogels for controlled drug 
delivery. Int. J. Pharm. 2009, 373, 41–47. 
51.  Herrlich, S.; Ziolek, S.; Hoefemann, H.; Zengerle, R.; Haeberle, S. Adjustable Diffusion Barrier 
for Controlled Drug Release in Spastic and Pain Therapy. In Proceedings of the 4th European 
Conference of the International Federation of Medical and Biological Engineering, Antwerp, 
Belgium, 23–27 November 2008; Springer: New York, NY, USA, 2009, Volume 22,   
pp. 2368–2371. 
52.  Mueller, K.F.; Heiber, S.J. Crosslinked, Porous Polymers for Controlled Drug Delivery. U.S. 
Patent 4,548,990, 22 October 1985. 
53.  Crotts, G.; Park, T.G. Preparation of porous and nonporous biodegradable polymeric hollow 
microspheres. J. Control. Release 1995, 35, 91–105.  
54.  Learoyd, T.P.; Burrows, J.L.; French, E.; Seville, P.C. Sustained delivery by leucine-modified 
chitosan spray-dried respirable powders. Int. J. Pharm. 2009, 372, 97–104. 
55.  Naveen, R. Biodegradable polymers in controlled drug delivery. Pharmainfo.net 2009. Available 
online: http://www.pharmainfo.net/raghanaveen/biodegradable-polymers-controlled-drug-delivery 
(accessed on 3 May 2010). 
56.  Heller, J.; Pangburn, S.H.; Penhale, D.W.H. Use of Bioerodible Polymers in Self-Regulated Drug 
Delivery Systems. In Controlled-Release Technology, Pharmaceutical Applications; Lee, P.I., 
Good, W.R., Eds.; ACS Symposium Series: Washington, DC, USA, 1987; pp. 172–187. 
57.  Harland, R.S.; Gazzaniga, A.; Sangalli, M.E.; Colombo, P.; Peppas, N.A. Drug/polymer matrix 
swelling and dissolution. Pharm. Res. 1998, 5, 488–494. 
58.  Lee, P.I. Kinetics of drug release from the hydrogel matrices. J. Control. Release  1985,  2,  
277–288. 
59.  Nelson, K.G.; Smith, S.J.; Bennet, R.M. Constant-Release Diffusion Systems: Rate Control by 
Means of Geometric Configuration. In Controlled-Release Technology, Pharmaceutical 
Applications; Lee, P.I., Good, W.R., Eds.; ACS Symposium Series: Washington, DC, USA, 1987; 
pp. 324–340. 
60.  Peppas, N.A.; Sahlin, J.J. A simple equation for the description of solute release: III. Coupling of 
diffusion and relaxation. Int. J. Pharm. 1989, 57, 162–172.  
61.  Narasimhan, B.; Langer, R. Zero-order release of micro and macromolecules from polymeric 
devices: The role of the burst effect. J. Control. Release 1997, 47, 13–20.  Int. J. Mol. Sci. 2012, 13                 
 
 
41
62.  Conte, U.; Maggi, L. A flexible technology for the linear, pulsatile and delayed release of drugs 
allowing for easy accommodation of difficult in vitro targets. J. Control. Release  2000,  64,  
263–268. 
63.  Zerbe, H.G.; Szabo, P. Oral Dosage Formulation. U.S. Pat. Appl. 20060127478, 15 June 2006. 
64.  Namdeo, B. Barrier layers in multilayered tablets. Express Pharma 2008. Available online: 
www.expresspharmaonline.com/20080731/research03.shtml (accessed on 24 October 2010). 
65.  Chidambaram, N.; Porter, W.; Flood, K.; Qui, Y. Formulation and characterisation of new 
layered diffusional matrices for zero-order sustained release. J. Control. Release  1998, 52,  
149–158.  
66.  Kim, C.J. Controlled release from triple layer, donut-shaped tablets with enteric polymers. AAPS 
PharmSci. 2005, 6, 429–436. 
67.  Shionogi Pharma, Inc. Once a day Sular
® (Nisoldipine) with Geomatrix
® delivery system for the 
treatment of hypertension. 2008. Available online: http://www.sular.com/html/geomatrix.html 
(accessed on 24 August 2010). 
68.  Patel, V.M.; Prajapati, B.G.; Patel, M.M. Formulation, evaluation, and comparison of bilayered 
and multilayered mucoadhesive buccal devices of propranolol hydrochloride. AAPS PharmSci. 
2007, 8, E147–E154. 
69.  Streubel, A.; Siepmann, J.; Peppas, N.A.; Bodmeier, R. Bimodal drug release achieved with 
multi-layer matrix tablets: Transport mechanisms and device design. J. Control. Release 2000, 
69, 455–468. 
70.  Efentakis, M.; Peponaki, C. Formulation study and evaluation of matrix and three-layer tablet 
sustained drug delivery systems based on carbopols with isosorbide mononitrate. AAPS PharmSci. 
2008, 9, 917–923. 
71.  Elan drug technologies. Spheroidal drug absorption system (SODAS
®). 2010. Available online: 
http://www.elandrugtechnologies.com/oral_controlled_release/sodas (accessed on 26 August 2010). 
72.  Ye, I.M.; Karasulu, H.; Ertan, G. Different geometric shaped hydrogel theophylline tablets: 
Statistical approach for estimating drug release. Farmaco 2003, 57, 939–945. 
73.  Hongtao, L.; Xiaochen, G.U. Correlation between drug dissolution and polymer hydration:   
A study using texture analysis. Int. J. Pharm. 2007, 342, 18–25.  
74.  Conti, S.; Maggi, L.; Segale, L.; Ochoa Machiste, E.; Conte, U.; Grenier, P.; Vergnault, G. 
Matrices containing NaCMC and HPMC: 2. Swelling and release mechanism study. Int. J. 
Pharm. 2007, 333, 143–151.  
75.  Li, H.; Hardy, R.J.; Gu, X. Effect of drug solubility on polymer hydration and drug dissolution 
from polyethylene oxide (PEO) matrix tablets. AAPS PharmSci. 2008, 9, 437–443. 
76.  Barakat, N.S.; Elbagory, I.M.; Almurshedi, A.S. Controlled-release carbamazepine matrix 
granules and tablets comprising lipophilic and hydrophilic components. Drug Deliv. 2009, 16, 
57–65. 
77.  Yang, L.; Johnson, B.; Fassihi, R. Determination of continuous changes in the gel layer thickness 
of poly(ethylene oxide) and HPMC tablets undergoing hydration: A textural analysis study. 
Pharm. Res. 1998, 15, 1902–1906. 
78.  Zerbe, H.G.; Krumme, M. Design Characteristics and Release Properties of a Novel   
Erosion-Controlled Oral Delivery System. In Modified-Release Drug Delivery Technology; Int. J. Mol. Sci. 2012, 13                 
 
 
42
Rathbone, M.J., Hadgraft, J., Roberts, M.S., Eds.; Marcel Dekker: New York, NY, USA, 2002; 
pp. 59–76, doi:10.1201/9780203910337.ch6. 
79.  Porter, S.C. Novel drug delivery: Review of current trends with oral solid dosage forms.   
Am. Pharm. Rev. 2009, 85, 28–35. 
80.  Doshi, M.M.; Joshi, M.D.; Mehta, B.P. Pharmaceutical Composition for Controlled Drug 
Delivery System. U.S. Patent 7,157,100, 2 January 2007. 
81.  Patra, C.N.; Kumar, A.B.; Pandit, H.K.; Singh, S.P.; Devi, M.V. Design and evaluation of 
sustained release bilayer tablets of propranolol hydrochloride. Acta Pharm. 2007, 57, 479–489. 
82.  Nirmal, J.; Saisivam, S.; Peddanna, C.; Muralidharan, S.; Godwinkumar, S.; Nagarajan, M. 
Bilayer tablets of Atorvastatin calcium and Nicotinic acid: Formulation and evaluation. Chem. 
Pharm. Bull. 2008, 56, 1455–1458. 
83.  Kim, S.W.; Jun, S.S.; Jo, Y.G.; Koo, J.S.; Jun, Y.S. Combination Formulation with Controlled 
Release Comprising Metformin and Glimepiride. WIPO Pat. Appl. WO/2008/050987,  
2 May 2008. 
84.  IntelGelx Corp. Innovative Drug Delivery Solutions. 2009. Available online: http:// 
www.intelgenx.com/_assets/pdf/Rodman-Renshaw-Sept-2009.pdf (accessed on 26 August 2010). 
85.  SkyePharma. A chronotherapy focused-real time oral drug delivery. 2010. Available online: 
http://www.skyepharma.com/ (accessed on 26 August 2010). 
86.  Maggi, L.; Shepard, T.; Rochdi, M.; Grenier, P.; Halbeisen, S.; Zimmer, R.; Conte, U.   
A Simulation Approach for Efficient Development of a Naproxen Geomatrix Quick/Slow 
Formulation. In Proceedings of the 24th International Symposium on Controlled Release of 
Bioactive Materials; The controlled release society: Stockholm, Sweden, 1997; pp. 327–328. 
87.  Desai, S. Multilayer Controlled Release Tablets Containing both Naproxen and Naproxen 
Sodium Salt. Eur. Patent EP 0656776, 20 March 1996. 
88.  Iyer, K.; Jha, R.J.; Saoji, D.G. Cardiovascular Therapeutic Combinations. WIPO Pat. Appl. 
WO/2006/085128, 17 August 2006. 
89.  Lopes, C.M.; Lobo, J.M.S.; Pinto, J.F.; Costa, P. Compressed mini-tablet as a biphasic delivery 
system. Int. J. Pharm. 2006, 303, 93–100. 
90.  Fukui, J.; Uemura, K.; Kobayashi, M. Studies on applicability of press-coated tablets using 
hydroxypropylcellulose (HPC) in the outer shell for timed-release preparations. J. Control. Release 
2000, 68, 215–223.  
91.  Siahi, M.R.; Barzegar-Jalali, M.; Monajjemzadeh, F.; Ghaffar, I.F.; Azarmi, S. Design and 
evaluation of 1- and 3-layer matrices of verapamil hydrochloride for sustaining its release.   
AAPS PharmSci. 2005, 6, 626–632. 
92.  Krishnaiah, Y.S.R.; Karthikeyan, R.S.; Gouri Sankar, V.; Satyanarayana, V. Three-layer guar 
gum matrix tablet formulations for oral controlled delivery of highly soluble trimetazidine 
dihydrochloride. J. Control Release 2002, 81, 45–56. 
93.  Longxiao, L.; Binjie, C. Preparation of monolithic osmotic pump system by coating the indented 
core tablet. Eur. J. Pharm. Biopharm. 2006, 64, 180–184. 
94.  Longxiao,
 L.; Xiangning, X.  Preparation of bilayer-core osmotic pump tablet by coating the 
indented core tablet. Int. J. Pharm. 2008, 352, 225–239. Int. J. Mol. Sci. 2012, 13                 
 
 
43
95.  Faour, J.; Mayorga, J. Multi-Layered Osmotic Device. U.S. Reissued Patent RE39069,  
18 April 2006. 
96.  Flanner, H.H.; Mcknight, L.C.; Burnside, B.A. System for Osmotic Delivery of Pharmaceutically 
Active Agents. U.S. Patent 6,838,093, 4 January 2005. 
97.  Liu, Q.; Fassihi, R. Zero-order delivery of a highly soluble, low dose drug alfuzosin 
hydrochloride via gastro-retentive system. Int. J. Pharm. 2008, 348, 27–34. 
98.  Yang, L.;  Eshragh, J.; Fassihi,  R. A new intragastric delivery system for the treatment of 
Helicobacter pylori associated gastric ulcer: In vitro evaluation. J. Control. Release 1999, 57, 
215–222. 
99.  Danckwerts, M.P. Development of a zero-order release oral compressed tablet with potential for 
commercial tabletting production. Int. J. Pharm. 1994, 112, 37–45.  
100.  Guimarães, G.G.; Katsuki, G.I.; Zanardo, N.D.; Ribeiro, D.A.; Cavalcanti, O.A. Evaluation of 
pectin-HPMC as compression coating. I–A study of the swelling properties of coated tablet. Rev. 
Bras. Cienc. Farm. 2008, 44, 133–141. 
101.  Cleave, J.P. Some geometrical considerations concerning the design of tablets. J. Pharm. 
Pharmacol. 1965, 17, 698–702. 
102.  Rhine, W.D.; Hsieh, D.S.T.; Langer, R. Polymers for sustained macromolecule release: 
Procedures to fabricate reproducible delivery systems and control release kinetics. J. Pharm. Sci. 
1980, 69, 265–270. 
103.  Hsieh, D.S.T.; Rhine, W.D.; Langer, R. Zero-order controlled release polymer matrices for micro 
and macromolecules. J. Pharm. Sci. 1983, 72, 17–22. 
104.  Kim, C.J. Compressed donut-shaped tablets with zero-order release kinetics. Pharm. Res. 1995, 
12, 1045–1048. 
105.  Cheng, K.; Zhu, J.; Song, X.; Sun, L.; Junhong, Z. Studies of hydroxypropylmethylcellulose 
donut-shaped tablets. Drug Dev. Ind. Pharm. 1999, 25, 1067–1071.  
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 